LigaChem Biosciences uses its in-house antibody-drug conjugate (ADC) linker technology to create drug candidates that it licenses out to global pharmaceutical companies. Rather than selling finished drugs directly, its main income comes from upfront payments, stage-based milestone fees and royalties, so revenue swings widely from year to year. Cumulative out-licensing deals total roughly ₩9 trillion, and four of its own ADC candidates are in clinical stages. In the first half of 2026 it won a US Phase 1/2 (IND) clearance for LCB02A, a CLDN18.2-targeting ADC candidate, and secured a ₩500 billion investment from the National Growth Fund, giving it the firepower to run late-stage trials itself. Two things stand out lately: with a validated ADC platform, ample cash and low debt, near-term financial risk is low, but as a clinical-stage company not yet earning a profit, its strength hinges on whether the pipeline clears the next clinical stages and further out-licensing follows, while clinical setbacks and the overhang from convertible bonds and convertible preferred shares are the cautions to weigh.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue rose 12.4% year over year, and the pace is slowing (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 30.4% lower than a year earlier.
- ROE is -18.0% (total-net basis). It is above the sector average.
- Operating margin is -75.2%.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder PAN ORION Corp. Limited 25.58% (corporate)
Controlling bloc incl. related parties 29.6%
With the controlling bloc holding 30%, control is maintained but the free float is relatively large.
🔎 In-depth analysis
- LigaChem Biosciences (formerly LegoChem Biosciences) uses its in-house antibody-drug conjugate technology - ADC, a therapy that attaches a potent anti-cancer drug to an antibody that precisely targets cancer cells, so it damages fewer healthy cells and attacks only cancer - to create drug candidates that it licenses out to global pharmaceutical companies.
- Its model is not to earn revenue by selling finished drugs directly; its main income comes from upfront payments at signing, stage-based milestone fees at each development and approval step, and royalties after commercialization.
- Because of this, revenue rises sharply in years when a large deal is struck and falls in years without one, swinging widely from year to year.
- Cumulative out-licensing deals signed to date total roughly ₩9 trillion, and four of its own ADC candidates are in clinical stages.
- The recent closing price is ₩118,200 and the market cap is ₩4.4 trillion.
- The price sits below both its 20-day line (₩139,105) and its 60-day line (₩161,187).
- It trades below both its short- and medium-term moving averages, so the trend is on the subdued side.
- The RSI (a supplementary gauge that weighs 14-day up-strength against down-strength on a 0-100 scale) is 38.5, a neutral level.
- The one-month change is -9.7%, the three-month change is -30.6%, and the price stands -44.6% from its 52-week high.
- Relative strength versus the KOSDAQ is 61 (1-99, converted from returns against the index over the past year with recent performance weighted more heavily; higher means stronger than the market).
- That places it in roughly the top 39% of all stocks by strength.
- Over the past three months it lagged the index by 7.7%.
- Chart readings are best viewed alongside trading volume and disclosure dates.
- Given the nature of a clinical-stage drug company, the profit-and-loss metrics are generally in the red.
- In 2025 it posted revenue of ₩141.6 billion with an operating loss of ₩106.5 billion and a net loss of ₩91.6 billion, an operating margin of -75.2% and ROE (how much is earned in a year per unit of equity) of -18.0%.
- With earnings negative, the P/E ratio (how many times one year's earnings the price is) cannot be calculated, and the P/B (how many times net assets the price is) comes out at 10.94 while the P/S (how many times revenue the price is) is 39.25 - both high.
- But these multiples reflect the nature of the business - a drug platform not yet earning a profit - so it is hard to call it expensive on absolute figures alone.
- Looking at the balance sheet itself, the debt ratio (debt to equity) is a low 31.7% and the current ratio (cash-like assets against debt due within a year) is a very ample 853%, so the losses do not stem from debt pressure but from R&D investment, and its financial capacity to keep running trials is on the sound side.
- Revenue grew from ₩32.2 billion five years ago to ₩141.6 billion in 2025, an average annual rate of about 45%, but this growth hinges not on product sales but on the timing at which upfront and milestone payments from out-licensing deals are recognized.
- In particular, a large deal booked in 2024 lifted revenue sharply.
- Indeed, Q1 2026 revenue of ₩35.9 billion fell 30.4% from a year earlier and the net loss widened to ₩33.3 billion, but this means it was a quarter without a large deal, not that the business deteriorated.
- Future earnings depend not on selling drugs directly but on the payments that arrive each time already out-licensed candidates (for example LCB84, licensed to Janssen) clear clinical stages, and on whether new out-licensing deals are signed.
- Since the timing and size of such income vary widely with deal completion, this company is best measured for growth by the clinical progress of its pipeline itself rather than by any single year's earnings multiple.
- The first half of 2026 brought both pipeline progress and capital-raising.
- In April it signed a new in-licensing deal to secure a new-mechanism drug, while, based on its assessment of results, it terminated some ADC joint-research and antibody in-licensing agreements to reorganize the pipeline.
- In May it won US Phase 1/2 clinical trial (IND) clearance for LCB02A, its own ADC candidate targeting CLDN18.2 - a target drawing attention in gastric and other cancers - opening the path into US trials.
- In June it secured a ₩500 billion investment from the National Growth Fund (₩170 billion in convertible bonds and ₩330 billion in convertible preferred shares); this was the National Growth Fund's first direct investment in a listed bio company, and largest shareholder Orion took part alongside it.
- The funds raised are earmarked for the capacity to run late-stage (Phase 2/3) trials of core pipeline assets in-house and for a next-generation ADC platform.
- The strengths are clear.
- The company holds a validated in-house platform in ADC - an anti-cancer technology in high demand worldwide - has a cumulative out-licensing track record of roughly ₩9 trillion and large partners such as Janssen, and has secured the firepower to run late-stage trials itself through a solid largest shareholder in Orion and the large June fundraising.
- With little debt and ample cash, near-term financial risk is also low.
- On the other hand, the cautions are just as clear.
- As a clinical-stage company not yet earning a profit, its bottom line may stay in the red for some time, and its revenue and earnings swing widely with individual deals and milestones.
- A clinical failure or a partner's development delay can feed straight into results and the share price, and the convertible bonds and convertible preferred shares issued in June could become an overhang as they convert into shares later.
- Ultimately, this stock is best read as one that strengthens on whether the pipeline clears the next clinical stages and further out-licensing follows - rather than on current earnings - and weakens when clinical setbacks or a prolonged out-licensing gap arise.
🔎 Valuation vs peers Inconclusive
Compared by drug-platform and out-licensing model rather than earnings multiples - contrasted against a domestic platform-bio peer that licenses its own core technology out to global pharma (Alteogen) and a peer that has commercialized its own drugs and reached profitability (SK Biopharmaceuticals).
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Alteogen | 113.48x | 36.11x | 31.82% |
| SK Biopharmaceuticals | 23.53x | 7.73x | 32.83% |
LigaChem Biosciences is a clinical-stage drug-platform company not yet earning a profit, so a P/E does not hold, and its P/B of 10.94 and P/S of 39.25 cannot be judged overvalued on absolute figures alone. The company's value rests not on net-asset or revenue multiples but on the clinical progress of already out-licensed candidates (for example Janssen's LCB84) and on the future payments from new out-licensing deals. Alteogen, which uses the same out-licensing model, also trades at a very high multiple to earnings, showing that this field is valued on pipeline worth rather than current earnings. For reference, LigaChem's P/B (10.9x) is far below Alteogen's (43.1x), so on an asset basis it is among the lower of the peer group, but this also reflects that it is still loss-making and that its results swing widely with individual deal completion. Since this is a stock for which undervalued versus overvalued cannot be split by earnings multiples, judgment on an earnings basis is withheld, and it is reasonable to assess it on the business substance of clinical and out-licensing progress.
Price history Close · MA20 · MA60
The latest close is ₩118,200 and the market capitalization is ₩4.4 trillion. The price sits below its 20-day moving average (₩139,105) and below its 60-day moving average (₩161,187). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 38.5, a neutral level. The one-month change is -9.7%, the three-month change is -30.6%, and the position relative to the 52-week high is -44.6%. Relative strength versus the KOSDAQ is 61 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 61% of all stocks. Over the past three months it lagged the index by 7.7%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -7.66% / 6M -18.82% / 12M -8.16%
Key metrics vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 8.62x is above the sector median (7.05x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
The operating margin is -75.2%. The debt ratio is 31.7%, so the financial structure is stable.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $22.6M | $83.4M | $93.8M | +12.43% ↓ slower |
| Operating profit | -$53.6M | -$13.9M | -$70.6M | — |
| Net profit | -$48.8M | $5.2M | -$60.7M | -1273.73% |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $21.3M | $22.1M | $22.6M | $83.4M | $93.8M |
| Operating profit | -$18.4M | -$33.4M | -$53.6M | -$13.9M | -$70.6M |
| Net profit | -$15.5M | -$29.9M | -$48.8M | $5.2M | -$60.7M |
| Revenue CAGR | 4-yr avg 44.85% | ||||
Revenue rose 12.4% year over year (2023 ₩34.1 billion → 2024 ₩125.9 billion → 2025 ₩141.6 billion), and the three-year trend is 'rising'. That said, the pace of growth slowed from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 5 years on record, revenue compound annual growth (CAGR) is 44.9%. The two-year revenue CAGR is 103.6%. In the most recent quarter (Q1 2026), revenue was 30.4% lower than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- Revenue grew 12.4% year over year, a sign of growth.
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
Recent news & events searched · sourced
- 2026-06-26FilingDecision to raise ₩500 billion with National Growth Fund participation via convertible bonds (₩170 billion) and a rights issue of convertible preferred shares (₩330 billion). Purpose: running late-stage trials in-house and investing in a next-generation ADC platform, with largest shareholder Orion taking part alongside.A medium- to long-term positive, securing funds to run late-stage (Phase 2/3) trials in-house and enlarging the capacity to realize pipeline value. That said, the convertible bonds and convertible preferred shares could become an overhang when they later convert into shares. Source
- 2026-05-14FilingUS IND clearance for the Phase 1/2 trial of LCB02A, the company's own CLDN18.2-targeting ADC candidate.Progress for the in-house pipeline via entry into US trials. A medium-term positive that lays the basis for further out-licensing and milestones once data are secured. Source
- 2026-04-06FilingSigned an in-licensing deal for R&D of a new-mechanism drug (expanding the pipeline).Diversifies the medium- to long-term pipeline by securing a next-generation candidate. Also a factor that raises in-house R&D costs. Source
- 2026-04-02UpdateTerminated some ADC joint-research and antibody in-licensing agreements based on its assessment of results (reorganizing the pipeline).Can be read positively as focusing resources by clearing out non-core projects, but halting individual projects can also read as a short-term contraction of the pipeline. Source
- 2026-05-15EarningsQ1 2026 quarterly report filed (revenue ₩35.9 billion, operating loss ₩37.4 billion, net loss ₩33.3 billion).A document confirming the reported results. The year-on-year revenue decline reflects the base effect of deal-driven income, and the loss reflects continued R&D spending. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Q1 2026 revenue and operating profit/loss | revenue ₩35.9 billion / ₩37.4 billion | revenue ₩35,888,235,410 / ₩37,417,536,384 | Confirmed | link |
| 2025 net loss | approx. -₩91.6 billion | 2025 | Confirmed | link |
| June fundraising size of ₩500 billion | base | ₩170.0 billion + ₩330.0 billion = ₩500.0 billion | Confirmed | link |
Recent filings
- 2026-06-01Large-business-group status disclosure
- 2026-05-15PeriodicQuarterly report
- 2026-05-14Amended filing
- 2026-05-14Disclosure
- 2026-05-14Disclosure
- 2026-04-29Disclosure
- 2026-04-28Fair-disclosure notice
- 2026-04-14Disclosure
- 2026-04-08Disclosure
- 2026-04-06Disclosure
- 2026-04-02Disclosure
- 2026-04-01OwnershipOfficers'/major-shareholders' holdings report
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.